Immediate Impact
3 standout
Citing Papers
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
2025 Standout
Randomised controlled trials evaluating artificial intelligence in clinical practice: a scoping review
2024 Standout
Works of Paul Kamudoni being referenced
The effect of disease modifying therapies on fatigue in multiple sclerosis
2023
Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Paul Kamudoni | 48 | 106 | 35 | 42 | 27 | 250 | |
| Teresa Monjardino | 20 | 42 | 22 | 23 | 25 | 283 | |
| Nicolás Medrano | 100 | 19 | 18 | 19 | 26 | 299 | |
| Arpan Patel | 43 | 89 | 66 | 6 | 26 | 274 | |
| Eliza Wasilewska | 7 | 42 | 27 | 10 | 30 | 217 | |
| N. Ben Achour | 26 | 30 | 6 | 14 | 43 | 260 | |
| Susana Clemente | 19 | 25 | 9 | 15 | 38 | 162 | |
| Enrique Alcalde-Cabero | 50 | 26 | 17 | 10 | 23 | 298 | |
| M. Treur | 15 | 61 | 60 | 26 | 32 | 297 | |
| Maria E. C. Schelin | 16 | 26 | 8 | 52 | 30 | 284 | |
| Birong Dong | 24 | 45 | 18 | 13 | 19 | 297 |
All Works
Login with ORCID to disown or claim papers
Loading papers...